Abstract: Organometallic compounds of the general formula (I), in which M=Mo, W, are claimed.

Abstract: Disclosed is a new dye for dye-sensitized solar cell and a solar cell prepared using the dye. A new compound of dye is esterificated to add carboxylate group to alkyl chain, thereby improving stability on electrolyte and semiconductor particles.

Abstract: The present invention provides a complex compound, etc., which has superior moisture- and heat-resistances, etc. and is used for an optical recording medium, including: a compound represented by Formula (I) below [in the formula, R1 represents an alkyl group which may have one or more substituents, etc., R2 represents a cyano group, etc., R3 represents an alkyl group which may have one or more substituents, etc., R4 represents a hydrogen atom, etc., R5 represents Formula (III) (in the formula, the ring A represents a heterocycle which may have one or more substituents, wherein the heterocycle is any one selected from a pyrimidine ring, a tetrazole ring, etc.)]; a metal; and any one ion selected from the group consisting of an ion formed by addition of one or more protons to an amine, an ammonium ion and a quaternary ammonium ion.

Abstract: Metal complex of Nickel (II) containing a dithio-based ligand have been synthesized and characterized by elemental analysis, mass spectrometry, Proton NMR and FT-IR spectrometry. A single crystal X-ray structure of the cadmium complex has been analyzed. The metal complex was subjected to biological tests on falcipain-2 (FP-2) and falcipain-3 (FP-3) cysteine protease enzymes from the malaria parasite Plasmodium falciparum. They were further tested in vitro against chloroquine resistant strain (W2). Whereas the potency of the metal complexes was weaker than the control regarding the FP-2 and FP-3, the potency of metal complexes was found to be exceedingly greater than the control when tested against the chloroquine resistant strain (W2) with a strength ratio of (1.4). This paper describes the synthesis, characterization and biological results of the said metal complex containing deprotonated 3-[1-(2-pyridyl) ethylidene] hydrazinecarbodithioate ligand.

Abstract: Silver(I) cyanoximates of AgL composition (L=NC—C(NO)—R, where R is electron withdrawing groups: —CN, —C(O)NR2, —C(O)R? (alkyl), —C(O)OEt, 2-heteroaryl fragments such as 2-pyridyl, 2-benzimidazolyl, 2-benzoxazolyl, 2-benzthiazolyl) are synthesized and characterized using spectroscopic methods and X-ray analysis. The synthesized compounds also demonstrate remarkable insensitivity toward visible light and UV-radiation. The combined characteristics of these compounds, such as light insensitivity, poor water solubility, high thermal stability, lack of toxicity of organic ligands, and antimicrobial activity make these silver(I) cyanoximates compounds suitable for use in biomaterial and medical devices.

Abstract: A composition including a Rh or Ru metalloinsertor complex specifically targets mismatch repair (MMR)-deficient cells. Selective cytotoxicity is induced in MMR-deficient cells upon uptake of the inventive metalloinsertor complexes.

Abstract: A metal complex dye, containing a ligand LL1 having a structure represented by Formula (I): wherein R1 and R2 represent a specific substituent; L1 and L2 represent a group composed of at least one kind of group selected from the group consisting of an ethenylene group, an ethynylene group and an arylene group, and conjugate with R1 or R2, and the bipyridine; the ethenylene group and the arylene group may be substituted or unsubstituted; R3 and R4 represent a substituent; n1 and n2 represent an integer of 0 to 3; A1 and A2 represent an acidic group or a salt thereof; and n3 and n4 represent an integer of 0 to 3.

Abstract: The present invention relates to novel iridium and/or rhodium containing complexes for use as a cytotoxic, such as an anti-cancer agent. There is also provided a method of preparing said compounds.

Abstract: Multi-metallic organometallic complexes that allow performance of olefin based reaction and in particular polymerization of olefins to produce polyolefin polymers, and related methods and systems are described.

Abstract: Embodiments of the present invention are generally directed to compositions comprising a class of molecular probes for detecting the presence of anionic cell surfaces. Embodiments include compositions that are enriched for these compositions and preparations, particularly preparations suitable for use as laboratory/clinical reagents and diagnostic indicators, either alone or as part of a kit. An embodiment of the invention provides for a highly selective agent useful in the discernment and identification of dead or dying cells, such as apoptotic cells, in a relatively calcium-free environment. An embodiment of the invention provides a selective agent for the identification of bacteria in a mixed population of bacterial cells and nonbacterial cells.

Abstract: Cationic palladium catalysts comprising diamino carbene ligands, wherein the catalysts are of the formula [Pd(X)q(LBX)t(DC)]r+[Ym-]p or [Pd(X)q(LB)n(LBX)t(DC)]2a+[V?]u[Z2?]y, wherein DC is a diamino carbene ligand, X is an anionic ligand, LBX is a combined anionic and neutral ligand, and Y, V, and Z are non-coordinating anions. The compounds are useful in catalytic reactions, including cross-coupling reactions and hydroamination reactions. In particular, the catalysts are used in the following reactions: Suzuki-Miyaura coupling, Kumada coupling, Negishi coupling, Sonogashira coupling, Hartwig-Buchwald amination, and Heck-Mizoroki coupling.

Abstract: The present invention relates to new rhenium compounds of formula (I) with medical utility, corresponding pharmaceutical compositions as well as medical uses thereof.

Abstract: The present invention relates generally to metal complexes, methods for preparation and uses of the same.

Abstract: A composition of matter suitable for the generation of hydrogen from water is described, the positively charged cation of the composition including the moiety of the general formula. [(PY5Me2)CoL]2+where L can be H20, OH?, a halide, alcohol, ether, amine, and the like. In embodiments of the invention, water, such as tap water or sea water can be subject to low electric potentials, with the result being, among other things, the generation of hydrogen.

Abstract: The invention relates to compounds fitting the following formula (I): A-T-Z ??(I) wherein: A is a group capable of being complexing at least one metal element, selected from pyridine, bipyridine, phenanthroline or phthalocyanine groups; T is a triazole group directly bound to group A; Z is a halogen atom, a nitro group, a cyano group, an alkyl group, an aryl group, a heterocyclic group, a group of formula —NR1R2, a group of formula —SR1, a group of formula —S(?O)2(OR1), a group of formula —O—S(?O)2(OR1), a group of formula —O—S(?O)2(R1), a group of formula —S(?O) (OR1), a group of formula —S(?O) (R1), a group of formula —S(?O)2R1, a group of formula —PR1R2, a group of formula —P(?O) (OR1) (OR2) , a group of formula —O—P (?O) (OR1) (OR2), a group of formula —O—P(?O) (OR1) (R2), a group of formula —OR1or a group of formula —CO—R1, and R2, independently represent a hydrogen atom, an alkyl group or an aryl group, said alkyl or aryl groups being optionally substituted.

Abstract: A metal complex of formula (III) wherein: M is a transition metal and A1, A2, X, X?, Y, L1?, R1? and R2? are as defined herein, is useful in medical imaging and therapy.

Abstract: The present invention relates to a process for preparing carbonates by reacting propylene oxide, ethylene oxide, styrene oxide and/or cyclohexene oxide with carbon dioxide in the presence of one or more catalysts of the formula I where R1 is hydrogen, C1-C6-alkyl, C1-C6-haloalkyl, NR?4—(CH2)2-6—where R? is C1-C6-alkyl; R2 is hydrogen, C1-C4-alkyl, C1-C4-haloalkyl, halogen, amino, nitro, C1-C6-alkoxy or cyano; R3, R4 are each hydrogen or together are a butadienylene moiety which bears the R5 substituent; R5 is C1-C4-alkyl, C1-C4-haloalkyl, halogen, amino, nitro, C1-C6-alkoxy or cyano; M is Zn(II), Mg(II), Cr(II), Cr(III), Co(II), Co(III), Fe(II) or Fe(III); and X1, X2 are each OCOCH3, OCOCF3, OSO2C7H7 or halogen. More particularly, the invention relates to a process for preparing cyclic carbonates, and to a process for preparing aliphatic polycarbonates using these catalysts I, and to particularly preferred catalysts of the formulae Ia and Ib.

Abstract: The present invention relates to a ruthenium complex and a photoelectric component using the same, and the ruthenium complex is represented by the following formula (I): RuL1L2(NCS)2Am??(I) wherein L1, L2, A and X are defined the same as the specification. The ruthenium complex of the present invention is suitable for a Dye-Sensitized Solar Cell (DSC). Hence, the photoelectric characteristics of the DSC manufactured with the ruthenium complex of the present invention are an improvement.

Abstract: Provided is a colored photosensitive curing composition useful for color filters in primary colors, including blue, green, and red, having a high molar absorption coefficient and allowing a reduction in film thickness and superior color purity and fastness. A colored photosensitive curing composition, comprising, as its colorant, a dipyrromethene-based metal complex compound obtained from a metal or metal compound and a dipyrromethene-based compound represented by the following Formula (I): wherein in Formula (I), R1 to R6 each independently represent a hydrogen atom or a substituent group; and R7 represents a hydrogen or halogen atom, or an alkyl, aryl or heterocyclic group.

Abstract: The present invention describes Photolabile Compounds methods for use of the compounds. The Photolabile Compounds have a photoreleasable ligand, which can be biologically active, and which is photoreleased from the compound upon exposure to light. In some embodiments, the Photolabile Compounds comprise a light antenna, such as a labeling molecule or an active derivative thereof. In one embodiment, the light is visible light, which is not detrimental to the viability of biological samples, such as cells and tissues, in which the released organic molecule is bioactive and can have a therapeutic effect. In another embodiment, the photoreleasable ligand can be a labeling molecule, such as a fluorescent molecule.

Abstract: The present invention provides a novel class of macrocyclic compounds as well as complexes formed between a metal (e.g., lanthanide) ion and the compounds of the invention. Preferred complexes exhibit high stability as well as high quantum yields of lanthanide ion luminescence in aqueous media without the need for secondary activating agents. Preferred compounds comprise hydroxypyridinonyl moieties within their macrocyclic structure and are characterized by surprisingly low, non-specific binding to a variety of polypeptides such as antibodies and proteins as well as high kinetic stability.

Abstract: Implementations and techniques for preparing and using monomers, oligomeric complexes, and coordination polymers are generally disclosed.

Abstract: Claimed are a compound of the general formula (I) and pharmaceutically acceptable salts thereof, where M signifies metal atoms selected independently from the group comprising Pd, Fe, Mn, Co, Ni, Cu, Zn and Mo; R1 and R2, independently of each other, signify hydrogen, amino, hydroxy, oxy, carboxy, cyano, C1-12alkyl, C2-12alkenyl, C2-12alkynyl, C1-12alkoxy, C1-12alkylamino, C1-12alkoxycarbonyl, C1-12alkylamido, arylamido, wherein the alkylene groupings in the given substituents can in turn be substituted by one or more of the following groups: hydroxy, oxy, carboxy, amino or amido; R3-R10, independently of each other, signify hydrogen; or NHR3R4 and NHR5R6, taken together, and/or NHR7R8 and NHR9R10, taken together, are a ligand (or ligands) containing one or several donor aliphatic or aromatic atoms of nitrogen and being in cis position on the metal atoms (M).

Abstract: A compound of Formula I, a pharmaceutically acceptable salt, or solvate thereof: complexes with metals such as rhenium, technetium, and others to provide a complex for imaging tissues or treating disease, particularly where the metal is radioactive. Such complexes are specific to PSMA protein and can therefore be used in imaging or treating cancer of the prostate and other tissue where the protein is expressed.

Abstract: A compound that recognizes and binds to the CA-IX protein has Formula I, II, III, or IV. The compounds may include a radioactive element for radioimaging or therapeutic applications. Thus, pharmaceutical compositions may be prepared with one or more of the compounds of Formula I, II, III, or IV.

Abstract: The present invention provides a new class of excited state intramolecular charge transfer (ESIPT) dye compounds based on mono or dihydroxy substituted 1,3-bisiminoisoindole motif and metal complexes containing such compounds as ligands. The present invention also provides OLEDs containing the compound and/or metal complex as the emissive material.

Abstract: The invention provides a method of treatment of cancer, wherein a individual doses of picoplatin, each of less than about 200 mg picoplatin content, the individual doses having high oral bioavailability, are administered to a patient in need thereof. The oral bioavailability can be greater than about 50%, or greater than about 75%, or greater than about 90%, depending upon the particular dosage form and dosing regimen used. The invention provides a quasi-metronomic dosing schedule including drug dosing intervals and drug intermission intervals, optionally including fasting periods prior to and following administration of each individual dose of picoplatin.

Abstract: An improved method for the synthesis of the anticancer drug picoplatin is provided. Condensation of a tetrachloroplatinate salt (TCP), such as potassium tetrachloroplatinate, and 2-picoline, in a solvent, is catalyzed by the presence of oxygen, such as in air, and additionally catalyzed by the presence of a Pt+4 complex, such as potassium hexachloroplatinate. The oxygen can be introduced into the reaction mixture by sparging, optionally with high shear mixing and under an inert gas headspace. The product trichloropicolineplatinate salt (TCPP) is a key intermediate in the synthesis of picoplatin, to which it can be converted by reaction of the TCPP with ammonia.

Abstract: Panchromatic photo sensitizers having a Formula of ML1L2X were synthesized, wherein M represents ruthenium atom; X represents a monodentate anion; L1 is heterocyclic bidentate ligand having one of formulae listed below: wherein G2 has one of formulae listed below: and L2 is a tridentate ligand having a formula listed below: Substituents R1, R2, R3 and R4 of L1 are the same or different and are selected from the group consisting of hydrogen, halogens, amino-group alkyl, alkoxy, alkylthio, alkylamino, halogenated alkyl, phenyl and substituted phenyl group. Substituents R5, R6 and R7 of L2 are the same or different and are selected from the group consisting of carboxylic acid and counter anion thereof, sulfonic acid and counter anion thereof, phosphoric acid and counter anion thereof. The above-mentioned photosensitizers are suitable to use as sensitizers for fabrication of high efficiency dye-sensitized solar cell.

Abstract: Reagents are provided for the introduction of phosphonate groups into fluorescent dyes. Methods are also provided for preparing dye conjugates.

Abstract: The invention relates to novel compositions of disubstituted bipyridyl osmium complexes useful for the synthesis of labeled proteins, nucleic acids, and for the modification of electrodes.

Abstract: This present invention provides new compounds for use as zinc ligand sensors in cellular imaging. These compounds are highly sensitive imagining agents that can be used with techniques such a laser scanning microscopy in intact cells in culture or in tissue preparations.

Abstract: A dye for dye-sensitized solar cells includes an organometallic complex represented by M(L)pX2:(Z)q. In the organometallic complex, M is a Group 8 through Group 10 metallic element, L is a bidentate ligand, X is a co-ligand, and Z is a counter-ion. The ratio of the bidentate ligand (L) to the counter-ion (Z) is about 1.1 to about 1.4. A method of preparing an exemplary dye includes mixing the organometallic complex with tetrabutylammonium thiocyanate and tetrabutylammonium hydroxide to prepare a solution, and purifying the solution at a pH of about 3.8 to about 4.1. A dye-sensitized solar cell includes a first electrode with a light absorbing layer, a second electrode and an electrolyte between the first and second electrodes. The light absorbing layer includes the dye.

Abstract: The present invention relates to modified surfaces. The surfaces comprise an inorganic material on which a phosphinic acid derivative is adsorbed. The phosphinic acid thus turns out to be a new anchoring group useful for surface derivatisation. The invention has many applications for photoelectric conversion devices, batteries, capacitors, electrochromic displays, chemical sensors, biological sensors, light emitting diodes, electrodes, semiconductors, separation membranes, selective adsorbents, adsorbents for HPLC, catalysts, implants, nanoparticles, antiadhesives, and anticorrosion coatings, for example.

Abstract: A compound which captures a multisite phosphorylated peptide or protein specifically to a phosphorylation site and a method for detecting the peptide or protein using the compound. Particularly, a compound which specifically detects an excessively phosphorylated tau protein observed in the brain affected by Alzheimer's disease and a method for diagnosing Alzheimer's disease in vitro or in vivo using the compound are provided. By bringing a metal complex compound having two dipicolylamine (Dpa) moieties and a spacer including a chromogenic or luminescent functional or atom group into contact with a multisite phosphorylated peptide or protein, the compound recognizes the distance between phosphate groups and specifically binds to the peptide or protein, and a multisite phosphorylated peptide or protein or kinase activity is optically detected by measuring the change, or a multisite phosphorylated peptide or protein or kinase activity is imaged by an optical imaging method applying the change in luminescence.

Abstract: Disclosed are benzoxazole-based compounds, kits, and methods of producing and using the described compounds in fluorescence-based detection of analytes (e.g., metal ions). Also disclosed are uses of benzoxazole-based compounds as ratiometric metal ion indicators.

Abstract: Pyridyldiamido transition metal complexes are disclosed for use in alkene polymerization.

Abstract: The present invention discloses organic and inorganic photosensitizer dyes as the following formulas (1) to (3), wherein the substituents “A, B, D and G” are as defined in claim 1.

Abstract: The present invention relates to the use of double-complex salts in electronic devices, in particular in organic electroluminescent devices, and oligomers formed from charged metal complexes.

Abstract: This invention provides a transition metal complex of formula MXY2Z and a manufacturing method thereof, wherein M is selected from iron, ruthenium, and osmium; X represents a ligand shown in formula (II) wherein R1 and R1? are independently selected from COOH, PO3H2, PO4H2, SO3H2, SO4H2, and derivatives thereof; Y is selected from H2O, Cl, Br, CN, NCO, NCS, and NCSe; Z represents a bidentate ligand having at least two fluorinated chains. In addition, this invention also provides photovoltaic cells and a manufacturing method thereof.

Abstract: A ruthenium complex having at least one selected from an alkyl thiophene unit and a unit in which thiophenes are linked to aromatic rings in the form of a pentagonal ring and a dye-sensitized solar cell using the same.

Abstract: Pyridyldiamido transition metal complexes are disclosed for use in alkene polymerization to produce multimodal polyolefins.

Abstract: The present invention relates to sequence selective compounds for targeting therapeutic or diagnostic groups to polynucleotides. More particularly, the present invention relates to sequence selective targeting of metallocomplexes, such as metallodrugs and metallodiagnostics, to polynucleotides.

Abstract: The present invention pertains to the double complex salts in optoelectronic components, like organic diodes, organic transistors or organic lasers, in particular an organic solar cell (OSC, OPP) and in particular from oligomers built from charged metal complexes.

Abstract: A dye sensitized solar cell, comprising a heteroleptic polypyridil complex of Ru, Os or Fe. The donating ligand has an extended conjugated n-system increasing the light absorbance and keeing the LUMO energy level higher than that of the anchoring ligand. A compacting compound whose molecular structure comprises a terminal group, a hydrophobic part and an anchoring group may be co-adsorbed together with the dye on the semi-conductive metal oxide layer of the photoanode, forming a dense mixed self-assembled monolayer.

Abstract: The hydrogen storage material of the invention is a hydrogen storage material comprising metal fine particles with hydrogen storage capacity, and an organic compound that has at least two specific groups that can bind with the metal fine particles, and that is bonded with the metal fine particles by the specific groups.

Abstract: Disclosed is a novel photosensitizer that can absorb light in a wide visible light region and in the case of a very thin film form, can enhance a light absorption efficiency by virtue of a large light absorption coefficient.

Abstract: A metal complex of formula (III) wherein: M is a transition metal and A1, A2, X, X?, Y, L1?, R1? and R2? are as defined herein, is useful in medical imaging and therapy.

Abstract: The present invention provides a compound of formula (I): PtIV(N3)2X1X2Y1Y2, wherein X1 and X2 are the same or different and each one is a group NR1R2R3 wherein R1, R2 and R3 are the same or different and each can be any one of H and optionally substituted alkyl, aryl, aralkyl, acyl, cycloalkyl, heterocyclyl, alkenyl, aralkenyl, alkinyl, cycloalkenyl, or X1 and X2 together represent a group R1R2NR4NR1R2 wherein R1 and R2 have the same meaning as before, and R4 represents an optionally substituted divalent, saturated or unsaturated, alkyl chain, an optionally substituted divalent, saturated or unsaturated cycloalkyl or an optionally substituted divalent aryl, or R4 or two or more of R1, R2, R3 and R4 and the respective N atom(s) to which they are linked, represent an optionally substituted heterocyclyl having at least one ring containing said N atom(s); and Y1 and Y2 are the same or different or when cis together represent a divalent moiety Y3, wherein at least one of Y1 and Y2, or Y3, is a substantially labil

Abstract: The present invention relates to a ruthenium complex and a photoelectric component using the same, and the ruthenium complex is represented by the following formula (I): RuL1L2(NCS)2Am??(I) wherein L1, L2, A and X are defined the same as the specification. The ruthenium complex of the present invention is suitable for a Dye-Sensitized Solar Cell (DSC). Hence, the photoelectric characteristics of the DSC manufactured with the ruthenium complex of the present invention are an improvement.